64Cu-DOTA-Rituximab PET/CT of B-Cell Non-Hodgkin Lymphoma for Imaging the CD20 Expression

Cu-64-DOTA-rituximab PET/CT was performed on a 62-year-old and a 71-year-old men diagnosed with B-cell non-Hodgkin lymphoma. Compared with F-18-FDG PET/CT, lesions could be detected more sensitively, and it was confirmed that there was no discernible Cu-64-DOTA-rituximab uptake in the tumor other than lymphoma. Cu-64-DOTA-rituximab PET/CT could be a powerful tool for the diagnosis and monitoring treatment response of lymphoma because of imaging the CD20 expression.

Automated summary

Cu-64-DOTA-rituximab PET/CT was performed on two patients with B-cell non-Hodgkin lymphoma, and it was found to be more sensitive in detecting lesions compared to F-18-FDG PET/CT. It was confirmed that there was no discernible Cu-64-DOTA-rituximab uptake in the tumor other than lymphoma. Cu-64-DOTA-rituximab PET/CT could be a powerful tool for the diagnosis and monitoring treatment response of lymphoma due to its ability to image CD20 expression.